What does this research mean for the field?

Cannabigerol and full-spectrum cannabis extract exert distinct analgesic and anti-inflammatory effects in inflammatory pain models, with the full-spectrum extract providing faster acute relief and cannabigerol producing more prolonged antinociception. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the therapeutic efficacy of cannabigerol (CBG) and standardized full-spectrum cannabis extract (FULL) in rat models of acute and chronic inflammatory pain and to assess their impact on inflammatory mediators.

September 5, 2026PsychopharmacologyOpen Access

Cannabigerol and standardized full-spectrum cannabis extract effects in acute and chronic inflammatory pain models

View Full Paper

Ask AI

Bookmark

Authors

DEDaniela Escobar-Espinal TFT. Fernandes RPRafaela Ponciano

Discussion

Member takes

Overview

Preclinical study reveals distinct pain relief and anti-inflammatory actions of cannabigerol and full extract in rats, suggesting complementary therapeutic potential.

Key Points

To evaluate the therapeutic efficacy of cannabigerol (CBG) and standardized full-spectrum cannabis extract (FULL) in rat models of acute and chronic inflammatory pain and to assess their impact on inflammatory mediators.
Tested analgesic responses in male Wistar Hannover rats using formalin-induced acute pain and complete Freund's adjuvant (CFA)-induced chronic inflammatory pain models.
Administered CBG or FULL at varying doses as a single acute dose or repeatedly once daily for 21 days, evaluating mechanical sensitivity and motor function via actimeter tests.
Measured levels of pro- and anti-inflammatory cytokines (TNF-α and IL-10) in plasma, spinal cord, and dorsal root ganglia using ELISA.
In acute pain, both cannabinoids reduced early Phase I nociception, but only FULL sustained analgesia through Phase II; in chronic pain, daily 10 mg/kg dosing produced earlier relief with FULL (day 10) and complete restoration of baseline sensitivity with CBG from day 15 onward.
Both treatments prevented CFA-induced locomotor impairments across tested regimens, except at the lowest dose of CBG.
Both cannabinoids prevented CFA-induced elevations of TNF-α in the plasma and spinal cord, whereas elevated TNF-α persisted in dorsal root ganglia and IL-10 levels remained unaltered.

Cite This Study

Escobar-Espinal et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec10c https://doi.org/10.1007/s00213-026-07156-y

View Full Paper

Ask AI

Bookmark

September 5, 2026PsychopharmacologyOpen Access

Cannabigerol and standardized full-spectrum cannabis extract effects in acute and chronic inflammatory pain models

View Full Paper

Ask AI

Bookmark

Authors

DEDaniela Escobar-Espinal TFT. Fernandes RPRafaela Ponciano

Discussion

Member takes

Overview

Preclinical study reveals distinct pain relief and anti-inflammatory actions of cannabigerol and full extract in rats, suggesting complementary therapeutic potential.

Key Points

To evaluate the therapeutic efficacy of cannabigerol (CBG) and standardized full-spectrum cannabis extract (FULL) in rat models of acute and chronic inflammatory pain and to assess their impact on inflammatory mediators.
Tested analgesic responses in male Wistar Hannover rats using formalin-induced acute pain and complete Freund's adjuvant (CFA)-induced chronic inflammatory pain models.
Administered CBG or FULL at varying doses as a single acute dose or repeatedly once daily for 21 days, evaluating mechanical sensitivity and motor function via actimeter tests.
Measured levels of pro- and anti-inflammatory cytokines (TNF-α and IL-10) in plasma, spinal cord, and dorsal root ganglia using ELISA.
In acute pain, both cannabinoids reduced early Phase I nociception, but only FULL sustained analgesia through Phase II; in chronic pain, daily 10 mg/kg dosing produced earlier relief with FULL (day 10) and complete restoration of baseline sensitivity with CBG from day 15 onward.
Both treatments prevented CFA-induced locomotor impairments across tested regimens, except at the lowest dose of CBG.
Both cannabinoids prevented CFA-induced elevations of TNF-α in the plasma and spinal cord, whereas elevated TNF-α persisted in dorsal root ganglia and IL-10 levels remained unaltered.

Cite This Study

Escobar-Espinal et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec10c https://doi.org/10.1007/s00213-026-07156-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark